STOCK TITAN
  1. Home
  2. Sec-filings
  3. OM
  4. [8-K] Outset Medical, Inc. Reports Material Event

[8-K] Outset Medical, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Outset Medical, Inc. reported a leadership change as Executive Vice President, R&D, Operations and Service, Marc Nash, has decided to depart the company. His role will end effective June 5, 2026, as he pursues other professional opportunities.

The company stated that Mr. Nash’s departure is not due to any dispute or disagreement with the company or its management, framing this as a voluntary transition rather than a conflict-driven exit.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Departure effective date June 5, 2026 Effective date of Marc Nash’s departure as EVP
Notice date May 26, 2026 Date Marc Nash informed the company of his decision
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Executive Vice President, R&D, Operations and Service financial
"his role as Executive Vice President, R&D, Operations and Service, effective June 5, 2026"
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Item 5.02 Departure of Directors or Certain Officers regulatory
"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"
Understanding 8-K Material Events →
0001484612false00014846122026-05-262026-05-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 26, 2026

Outset Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39513

20-0514392

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

3052 Orchard Dr.,

San Jose, California

95134

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (669) 231-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

OM

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 26, 2026, Marc Nash informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company and his role as Executive Vice President, R&D, Operations and Service, effective June 5, 2026, to pursue other professional opportunities. Mr. Nash’s departure is not due to any dispute or disagreement with the Company or its management.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Outset Medical, Inc.

 

Date: May 29, 2026

By:

/s/ John Brottem

John Brottem

General Counsel

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Other Documents